Cargando…
Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer
Distinguishing clinically significant from indolent prostate cancer (PC) is a major clinical challenge. We utilised targeted protein biomarker discovery approach to identify biomarkers specific for pro-metastatic PC. Serum samples from the cancer-free group; Cambridge Prognostic Group 1 (CPG1, low r...
Autores principales: | Liu, Shiqin, Shen, Michelle, Hsu, En-Chi, Zhang, Chiyuan Amy, Garcia-Marques, Fernando, Nolley, Rosalie, Koul, Kashyap, Rice, Meghan A., Aslan, Merve, Pitteri, Sharon J., Massie, Charlie, George, Anne, Brooks, James D., Gnanapragasam, Vincent J., Stoyanova, Tanya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921397/ https://www.ncbi.nlm.nih.gov/pubmed/33288843 http://dx.doi.org/10.1038/s41416-020-01200-0 |
Ejemplares similares
-
Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay
por: Liu, Shiqin, et al.
Publicado: (2021) -
MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer
por: Hsu, En-Chi, et al.
Publicado: (2021) -
Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1
por: Hsu, En-Chi, et al.
Publicado: (2020) -
Oncogene-mediated metabolic gene signature predicts breast cancer outcome
por: Aslan, Merve, et al.
Publicado: (2021) -
Quantifying the invasion and migration ability of cancer cells with a 3D Matrigel drop invasion assay
por: Aslan, Merve, et al.
Publicado: (2021)